Table 3

Cox proportional hazards model for analysis of drug retention of secukinumab versus an alternative TNFi after prior exposure to one or more TNFis

Method	Variable	All patients with axSpA N=390; N_events=203			ASAS-positive patients with axSpA N=252 ; N_events=129
Method	Variable	HR	95% CI	P value	HR	95% CI	P value
Propensity score based	Secukinumab versus TNFi	1.14	0.78 to 1.68	0.50	1.20	0.74 to 1.94	0.47
Covariate adjustment	Secukinumab versus TNFi	1.16	0.79 to 1.71	0.45	1.30	0.81 to 2.09	0.27
	Age	1.01	1.00 to 1.03	0.12	1.01	0.99 to 1.03	0.41
	Female versus male sex	1.46	1.02 to 2.07	0.04	1.47	0.95 to 2.27	0.08
	ASDAS	1.28	0.98 to 1.68	0.07	1.39	1.02 to 1.89	0.03
	BASFI	1.03	0.92 to 1.16	0.59	1.01	0.88 to 1.16	0.94
	BASMI	0.95	0.80 to 1.14	0.60	0.98	0.76 to 1.25	0.84
	HLA-B27 positive versus negative	1.15	0.82 to 1.61	0.42	0.89	0.58 to 1.37	0.59
	Enthesitis, yes versus no	1.04	0.71 to 1.50	0.85	0.91	0.56 to 1.49	0.71
	Peripheral arthritis, yes versus no	0.94	0.67 to 1.33	0.73	0.92	0.58 to 1.47	0.73
	Non-radiographic, versus radiographic axspA	1.38	0.80 to 2.41	0.25	1.30	0.72 to 2.35	0.39
	Ever psoriasis, yes versus no	1.18	0.74 to 1.88	0.49	1.07	0.56 to 2.05	0.83
	Ever uveitis, yes versus no	0.80	0.50 to 1.27	0.34	0.93	0.52 to 1.67	0.81
	Ever inflammatory bowel disease, yes versus no	0.99	0.55 to 1.80	0.98	1.31	0.62 to 2.75	0.47
	Current smoking, yes versus no	0.97	0.61 to 1.53	0.88	0.77	0.44 to 1.35	0.37
	BMI ≤25 kg/m² versus BMI >25 kg/m²	1.11	0.80 to 1.53	0.54	1.02	0.69 to 1.52	0.91
	Reason for discontinuation of prior TNFi (other vs ineffectiveness)	0.84	0.62 to 1.15	0.28	0.81	0.55 to 1.20	0.29
	Later-line versus second-line bDMARDs	0.95	0.69 to 1.31	0.76	1.07	0.72 to 1.59	0.74

HR for discontinuation of secukinumab versus TNFi is shown in bold as the result of main interest for both methods of analysis used (matched-weight propensity score approach and covariate-adjusted analysis, respectively).
ASAS, Assessment in SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; HLA-B27, human leucocyte antigen B27; TNFi, tumour necrosis factor inhibitor.